Peginterferon (alpha)-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response

MLA

Kamal, S. M., et al. “Peginterferon (Alpha)-2b and Ribavirin Therapy in Chronic Hepatitis C Genotype 4: Impact of Treatment Duration and Viral Kinetics on Sustained Virological Response.” Gut, vol. 54, no. 6, June 2005, p. 858. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.139409781&authtype=sso&custid=ns315887.

APA

Kamal, S. M., El Tawil, A. A., Nakano, T., He, Q., Rasenack, J., Hakam, S. A., Saleh, W. A., Ismail, A., Aziz, A. A., & Madwar, A. M. (2005). Peginterferon (alpha)-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut, 54(6), 858.

Chicago

Kamal, S.M., A.A. El Tawil, T. Nakano, Q. He, J. Rasenack, S.A. Hakam, W.A. Saleh, A. Ismail, A.A. Aziz, and Ali M. Madwar. 2005. “Peginterferon (Alpha)-2b and Ribavirin Therapy in Chronic Hepatitis C Genotype 4: Impact of Treatment Duration and Viral Kinetics on Sustained Virological Response.” Gut 54 (6): 858. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.139409781&authtype=sso&custid=ns315887.